Cargando...

Systemic treatment for metastatic prostate cancer

The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Asian J Urol
Autor Principal: Gravis, Gwenaelle
Formato: Artigo
Idioma:Inglês
Publicado: Second Military Medical University 2019
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6488732/
https://ncbi.nlm.nih.gov/pubmed/31061802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2019.02.002
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!